AVASTIN (bevacizumab), monoclonal antibody - RENAL CELL CARCINOMA
ONCOLOGY - Focus
Opinions on drugs -
Posted on
Jun 27 2016
Reason for request
Re-assessment of the improvement in actual benefit
Significant clinical interest without demonstrated clinical benefit in combination with interferon in the first-line management of advanced and/or metastatic renal cell carcinoma, in the absence of data versus clinically relevant comparators (sunitinib and pazotinib)
- In renal cell carcinoma, AVASTIN has marketing authorisation in combination with interferon alpha-2a, in the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma.
- The addition of bevacizumab to interferon improves progression-free survival by 4.8 months relative to interferon alone. No conclusion on the contribution of AVASTIN to overall survival is possible.
- New comparative efficacy data versus interferon alone, which is no longer a standard strategy, do not allow quantifying its contribution in this indication.
- In combination with interferon, it is a treatment option in the first-line management of advanced and/or metastatic renal cell carcinoma with a good or intermediate prognosis.
Clinical Benefit
Substantial |
- |
Clinical Added Value
no clinical added value |
- |
English version
Contact Us
Évaluation des médicaments